Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma
European Oncology & Haematology, 2017;13(1):61-5. DOI: https://doi.org/10.17925/EOH.2017.13.01.1a
touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.